Drug Manufacturers - Specialty & Generic · NYSE
当前价格
$113.32
内在价值
使用下方计算器估算
对 Zoetis Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Earnings Yield
5.38%
ROE (TTM)
58.2%
基于过去 12 个月的数据，ZTS 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
ZTS 的过去 12 个月市盈率反映投资者为 Zoetis Inc. 每一美元收益所支付的价格。该指标在与Drug Manufacturers - Specialty & Generic同类公司和公司自身历史区间对比时最有意义。
ZTS 是否被高估取决于将其市盈率与Drug Manufacturers - Specialty & Generic同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估，但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 Zoetis Inc. 使用 PE 估值的步骤：(1) 将当前市盈率与Drug Manufacturers - Specialty & Generic中位数对比评估相对定价，(2) 查看 PEG 比率以调整增长预期，(3) 参考 5 年 PE 历史区间判断当前位置，(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速，提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估，高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——ZTS 相对于Drug Manufacturers - Specialty & Generic同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 ZTS，ROE 达到 58.2%，两种方法都值得使用——PE 做市场对比，DCF 验证基本面是否支撑当前价格。两种方法各有盲区：PE 忽略了资本结构和现金流质量，DCF 则对增长率和折现率假设非常敏感。
